Resmed 1QFY15 earnings summary

Scott Power

Morgans

Resmed 1QFY15 underlying earnings were in line with expectations, with another quarter of double-digit sales growth, underpinned by strong US flow generator uptake and continued strength in masks beating market growth rates. While ROW sales continue to be impacted by disappointing SERVE-HF trial results, the impact remains ring-fenced and failed to detract from market-tracking growth across product categories and robust sales in APAC. We remain confident 1Q marks the earnings nadir, with momentum increase throughout the year as the pricing environment is stable, cost-out initiatives take hold, FX headwinds abate and the value-enhancing healthcare informatics platform continues to drive channel efficiencies. (RMD, Add, Price Target A$8.86)


1 stock mentioned

Scott Power
Scott Power
Senior Analyst
Morgans

Senior Analyst at Morgans covering healthcare, life science, telecommunications, technology and media. I've spent the last twenty years investing in and researching emerging companies and have developed a wide network of contacts across these...

Expertise

No areas of expertise

I would like to

Only to be used for sending genuine email enquiries to the Contributor. Livewire Markets Pty Ltd reserves its right to take any legal or other appropriate action in relation to misuse of this service.

Personal Information Collection Statement
Your personal information will be passed to the Contributor and/or its authorised service provider to assist the Contributor to contact you about your investment enquiry. They are required not to use your information for any other purpose. Our privacy policy explains how we store personal information and how you may access, correct or complain about the handling of personal information.